July 12, 2018 — Today, Socium Therapeutics announced that Anna Ferrari, MD has joined the company’s Scientific Advisory Board. Dr. Ferrari is a medical oncologist and clinical researcher dedicated to prostate cancer research. Her experience includes clinical practice and basic laboratory science investigations geared towards preclinical testing for clinical trial development in prostate cancer. Dr. Ferrari joined Rutgers Cancer Institute of New Jersey as the Director of the Genitourinary (GU) Cancer Program and Professor of Medicine. Previously, she served as Co-Director of Genitourinary (GU) Program for NYU Perlmutter Cancer Center, and prior to that spent several years at Mount Sinai School of Medicine, serving as Director of the Genitourinary Cancer Program.
As a member of the Genitourinary Committee and Prostate Cancer Clinical Trials Consortium, Dr. Ferrari helps develop clinical trials for prostate cancer on a national level. For many years she played a major role in the clinical trials that lead to the approval of Provenge®, the first FDA approved vaccine for treatment of prostate cancer. Dr. Ferrari also currently active in the development of new agents and vaccines that are highly promising for prostate cancer patients.